Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia):

Description Percentage

Requiring peripheral blood or bone marrow stem cell transplant, or continuous myelosuppressive or immunosuppressive therapy treatment

Description Percentage

Requiring intermittent myelosuppressive therapy, or molecularly targeted therapy with tyrosine kinase inhibitors, or interferon treatment when not in apparent remission

Description Percentage

In apparent remission on continuous molecularly targeted therapy with tyrosine kinase inhibitors


Note (1): If the condition undergoes leukemic transformation, evaluate as leukemia under Vdiagnostic code 7703.

Note (2): A 100 percent evaluation shall be assigned as of the date of hospital admission for peripheral blood or bone marrow stem cell transplant; or during the period of treatment with chemotherapy (including myelosuppressants). Six months following hospital discharge or, in the case of chemotherapy treatment, six months after completion of treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any reduction in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105 of this chapter.

Need help with Medical Compensation? If your disability claim is not clearly supported by your medical records along with evidence, your claim can be denied. We have helped thousands of Veterans claim the compensation they deserve.

Get More Info